QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia

NCT06456528 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

235

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer Treatment-Induced Thrombocytopenia

Interventions

DRUG: QL0911
DRUG: QL0911 plus Placebo
DRUG: Placebo

Sponsor

Qilu Pharmaceutical Co., Ltd.